Colgate Women’s Games Returns for 48th Season

Registration for the Nation’s Longest-Running Track & Field Series for Girls and Women is Now Open Colgate-Palmolive Doubles the Value of Scholarships for 2023 Season ShopRite Joins as Supporter for 2023 Games NEW YORK–(BUSINESS WIRE)–#CSR–Today, Colgate-Palmolive (NYSE:CL) announced that Colgate...

GSR Launches Foundation with $10m Pledge Celebrating 10 years of Business

Additionally Appoints Founding Director James Newell to Build Strategy LONDON–(BUSINESS WIRE)–#OTC–GSR, the global crypto market maker and liquidity provider, has pledged an initial $10m to establish the GSR Foundation, an independent grantmaking charity that will support non-profit organisations across the...

Ocean Biomedical Debuts as Publicly Traded Company

Ocean Biomedical Debuts as Publicly Traded Company

  By Healthcare Edge Editorial Staff Biopharma company Ocean Biomedical (Nasdaq: OCEA) began trading publicly today after merging with a SPAC called Aesther Healthcare Acquisition Corp. (Nasdaq: AEHA). Ocean Biomedical is focused on the commercialization of assets from research universities...

Ocean Biomedical Debuts as Publicly Traded Company

Ocean Biomedical Debuts as Publicly Traded Company

By Exec Edge Editorial Staff Biopharma company Ocean Biomedical (Nasdaq: OCEA) began trading publicly today after merging with a SPAC called Aesther Healthcare Acquisition Corp. (Nasdaq: AEHA). Ocean Biomedical is focused on the commercialization of assets from research universities and...

Plus Therapeutics: Targeting Brain Cancer with Rifle-Shot Precision

Plus Therapeutics: Targeting Brain Cancer with Rifle-Shot Precision

Plus Therapeutics, Inc. (Nasdaq: PSTV) specializes in targeted radiation treatments Rather than traditional radiation beams, Plus uses needle-sized applicators into brain fluid Focused on brain cancer which is difficult to reach through blood-brain barrier Targets 2 rare cancers: recurrent glioblastoma...

AEON Biopharma Investors Contribute Additional $20 Million to SPAC Deal

AEON Biopharma Investors Contribute Additional $20 Million to SPAC Deal

By IPO Edge Editorial Staff Biopharmaceutical company AEON Biopharma, Inc. has raised an additional $20 million in funding from existing investors to support its going-public transaction with Priveterra Acquisition Corp. (Nasdaq: PMGM). The additional capital represents nearly half of the...

Input your search keywords and press Enter.